Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes and Liquid Biopsies Asia 2016

Eric Yang's Biography

Eric Yang, Quark Biosciences, Director of Application Development

Dr. Eric Yang is the Director of Application Development at Quark Biosciences, a Xinzhu-based biotechnology firm which develops proprietary qPCR array technology as well as clinical diagnostic products. Dr. Yang currently spearheads several major projects at the company, including the development of non-invasive cancer diagnostic tests using blood-based microRNAs. At present, his effort has led to a number of collaborations with prominent Taiwanese hospitals and key opinion leaders. Dr. Yang grew up in Taiwan and left to attend college at the University of California, Los Angeles (UCLA). After receiving his bachelor’s degree in Biochemistry, he joined the laboratory of Guillaume Chanfreau at UCLA to further his studies in Molecular Biology. His doctoral thesis focused on deciphering the biogenesis of essential non-coding RNAs responsible for the modifications of ribosomal RNAs. His research effort has led to several grant approvals and awards. Upon receiving his Ph.D., Dr. Yang continued his research in long non-coding RNAs as a Howard Hughes Medical Institute Scholar at Harvard Medical School. There, he co-authored a number of key papers and a major review on the roles of non-coding RNAs.

Eric Yang Image

A Multifunctional qPCR Array for Large-Scale, Routine Analysis of Circulating Tumor Nucleic Acids (ctNAs)

Thursday, 7 April 2016 at 15:30

Add to Calendar ▼2016-04-07 15:30:002016-04-07 16:30:00Europe/LondonA Multifunctional qPCR Array for Large-Scale, Routine Analysis of Circulating Tumor Nucleic Acids (ctNAs)Exosomes and Liquid Biopsies Asia 2016 in Taipei, TaiwanTaipei,

microRNAs are increasing being recognized as a novel class of cancer molecular biomarkers with distinct advantages. Over the past decades, numerous publications have illustrated that microRNAs can be of diagnostic, prognostic and predictive values in the field of oncology. Utilizing PanelChip™, a qPCR array technology developed by Quark Biosciences, we’ve looked at the level of 160 microRNAs in the plasma of oral cancer patients before and after surgery. In addition, we’ve also examined the exosomal miRNAs of these patients. Preliminary result suggests that PanelChip™ can be of a powerful tool to screen and validate cell-free miRNA biomarkers for translational medical researchers. Combining the PanelChip™ platform with our on-going effort to build a cancer-based miRNA database, Quark Biosciences aims to become the leading solution provider for microRNA research.

Add to Calendar ▼2016-04-07 00:00:002016-04-08 00:00:00Europe/LondonExosomes and Liquid Biopsies Asia 2016Exosomes and Liquid Biopsies Asia 2016 in Taipei, TaiwanTaipei,